deCode, Illumina in diagnostic deal

DCGN and ILMN partnered to develop and commercialize diagnostic tests for gene variants discovered by DCGN using ILMN's high-multiplex SNP genotyping platform. The partners will jointly validate biomarkers, and ILMN will sell resulting diagnostic panels for use on its planned BeadXpress platform. The companies will share costs and profits. The companies initially will focus on developing tests for the genes encoding leukotriene A4 hydrolase (LTA4H), transcription factor 7-like 2 (TCF7L2) and BARD1, which the companies said are linked to heart attack, Type II diabetes and breast cancer, respectively. ...